X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/asco-2024--ascentage-pharma-to-present-four-studies-including-an-oral-report-featuring-the-latest-data-of-olverembatinib-in-sdh-deficient-gist-302126836.html
https://www.prnewswire.com/news-releases/global-registrational-phase-iii-study-of-olverembatinib-hqp1351--cleared-by-fda-302061303.html
https://www.prnewswire.com/news-releases/olverembatinib-included-in-newest-guidelines-on-chronic-myeloid-leukemia-cml-management-from-the-national-comprehensive-cancer-network-nccn-302036514.html
https://www.prnewswire.com/news-releases/live-from-ash-2023--oral-report-featuring-encouraging-data-of-olverembatinib-combined-with-reduced-intensity-chemotherapy-in-patients-with-ph-all-presented-at-the-ash-annual-meeting-302016262.html
https://www.prnewswire.com/news-releases/live-from-ash-2023--results-from-chinese-studies-of-olverembatinib-presented-in-oral-report-at-the-ash-annual-meeting-for-the-sixth-consecutive-year-including-data-showing-promising-efficacy-in-patients-with-tki-resistant-andor-302013804.html
https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-presents-updated-data-from-us-study-of-olverembatinib-further-validating-encouraging-efficacy-in-patients-resistant-to-ponatinib-or-asciminib-302011011.html
https://www.prnewswire.com/news-releases/ascentage-pharma-hosts-ceremony-marking-the-launch-of-olverembatinib-in-newly-approved-indication-and-the-dispatch-of-first-batch-for-the-new-indication-301997142.html
https://www.prnewswire.com/news-releases/ash-2023--for-the-sixth-consecutive-year-results-from-multiple-clinical-studies-of-olverembatinib-have-been-selected-for-presentations-including-two-oral-reports-at-the-2023-ash-annual-meeting-301976607.html
https://www.prnewswire.com/news-releases/first-patient-dosed-in-the-registrational-phase-iii-study-of-olverembatinib-in-treatment-naive-patients-with-philadelphia-chromosome-positive-ph-acute-lymphoblastic-leukemia-all-301959890.html
https://www.prnewswire.com/news-releases/registrational-pivotal-phase-iii-study-of-olverembatinib-for-the-first-line-treatment-of-patients-with-ph-all-approved-by-the-cde-in-china-301870768.html
https://www.prnewswire.com/news-releases/innovent-announces-the-second-breakthrough-therapy-designation-by-nmpa-for-olverembatinib-for-the-treatment-of-patients-with-sdh-deficient-gist-301841691.html
https://www.prnewswire.com/news-releases/ascentage-pharmas-novel-drug-olverembatinib-recommended-for-a-breakthrough-therapy-designation-in-china-for-the-treatment-of-sdh-deficient-gist-the-second-btd-for-the-drug-301838020.html
https://www.prnewswire.com/news-releases/innovent-announces-inclusion-in-the-china-national-reimbursement-drug-list-nrdl-of-tyvyt-in-two-new-indications-olverembatinib-for-the-first-listing-byvasda-halpryza-and-sulinno-in-multiple-new-indications-301724754.html
https://www.prnewswire.com/news-releases/chinas-first-and-only-approved-third-generation-bcr-abl-inhibitor-olverembatinib-included-into-the-2022-national-reimbursement-drug-list-301725452.html
https://www.prnewswire.com/news-releases/live-from-ash-2022--ascentage-pharma-delivers-oral-report-on-the-first-dataset-from-the-us-study-of-olverembatinib-hqp1351-with-promising-efficacy-observed-in-patients-who-failed-prior-treatment-with-ponatinib-301699947.html
https://www.prnewswire.com/news-releases/ash-2022--ascentage-pharma-to-present-data-of-olverembatinib-hqp1351-in-three-oral-reports-including-the-first-dataset-from-the-first-us-study-at-the-ash-annual-meeting-301668292.html
https://www.prnewswire.com/news-releases/ascentage-pharma-announces-phase-iii-data-of-olverembatinib-hqp1351-published-in-the-journal-of-hematology--oncology-further-validating-the-drugs-best-in-class-potential-301629866.html
https://www.prnewswire.com/news-releases/innovent-and-ascentage-pharma-announce-the-china-nmpa-accepted-and-granted-priority-review-designation-to-a-new-drug-application-for-olverembatinib-for-the-treatment-of-drug-resistant-cml-301588946.html
https://www.prnewswire.com/news-releases/asco-2022--the-first-dataset-of-olverembatinib-hqp1351-in-patients-with-gist-demonstrates-therapeutic-potential-with-a-clinical-benefit-rate-of-83-3-301562391.html
http://www.chinadaily.com.cn/a/202112/20/WS61c04c31a310cdd39bc7c77e.html
https://www.prnewswire.com/news-releases/ash-2021--ascentage-pharma-releases-long-term-clinical-data-of-olverembatinib-hqp1351-in-oral-presentation-demonstrating-efficacy-and-safety-301444263.html
https://www.prnewswire.com/news-releases/ascentage-pharmas-olverembatinib-granted-orphan-designation-by-the-european-commission-for-the-treatment-of-chronic-myeloid-leukemia-301429860.html
https://www.prnewswire.com/news-releases/ash-2021--ascentage-pharma-to-present-three-studies-of-olverembatinib-hqp1351-a-novel-drug-candidate-for-the-treatment-of-drug-resistant-leukemia-in-abstracts-including-one-oral-report-at-ash-annual-meeting-301417333.html
https://www.prnewswire.com/news-releases/ascentage-pharma-announces-positive-data-from-pivotal-phase-ii-studies-of-hqp1351-olverembatinib-in-patients-with-tki-resistant-chronic-myeloid-leukemia-cml-at-2020-american-society-of-hematology-ash-annual-meeting-301187820.html
Market Place
Share 
